In vivo emergence of HIV-1 highly sensitive to neutralizing antibodies

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Aasa Chapman, Marlén M I ^a   Cheney, Kelly M ^b   Hué, Stéphane ^a   Forsman, Anna ^a   O'Farrell, Stephen ^c   Pellegrino, Pierre ^c   Williams, Ian ^c   McKnight, Áine ^a,b  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EPITOPE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1B12; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 17B; MONOCLONAL ANTIBODY 2G12; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS RECEPTOR;

ARTICLE; BINDING SITE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VIVO STUDY; MACROPHAGE; MALE; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; SEROCONVERSION; SERUM; VIRAL TROPISM; VIRUS ATTACHMENT; VIRUS ENVELOPE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE EVASION; IMMUNOLOGY; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIBODIES, NEUTRALIZING; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE EVASION; VIRUS REPLICATION;

EID: 80051999598     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023961     Document Type: Article

References (50)

1. Wyatt R, Sodroski J, (1998) The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280: 1884-1888.
2. Clapham PR, McKnight A, (2002) Cell surface receptors, virus entry and tropism of primate lentiviruses. J Gen Virol 83: 1809-1829.
3. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, et al. (2001) Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75: 10892-10905.
4. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, et al. (2001) A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 17: 1757-1765.
5. Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, et al. (2001) Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293: 1155-1159.
6. Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 5: e8805.
7. Roben P, Moore JP, Thali M, Sodroski J, Barbas CF, 3rd, et al. (1994) Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 68: 4821-4828.
8. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, et al. (1994) Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266: 1024-1027.
9. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, et al. (1996) Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70: 1100-1108.
10. Ditzel HJ, Binley JM, Moore JP, Sodroski J, Sullivan N, et al. (1995) Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure. J Immunol 154: 893-906.
11. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285-289.
12. Albert J, Abrahamsson B, Nagy K, Aurelius E, Gaines H, et al. (1990) Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4: 107-112.
13. McKnight A, Clapham PR, Goudsmit J, Cheingsong-Popov R, Weber JN, et al. (1992) Development of HIV-1 group-specific neutralizing antibodies after seroconversion. Aids 6: 799-802.
14. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312.
15. Richman DD, Wrin T, Little SJ, Petropoulos CJ, (2003) Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100: 4144-4149.
16. Aasa-Chapman MM, Hayman A, Newton P, Cornforth D, Williams I, et al. (2004) Development of the antibody response in acute HIV-1 infection. Aids 18: 371-381.
17. Gray ES, Moore PL, Choge IA, Decker JM, Bibollet-Ruche F, et al. (2007) Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol 81: 6187-6196.
18. Krachmarov CP, Kayman SC, Honnen WJ, Trochev O, Pinter A, (2001) V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 17: 1737-1748.
19. Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, et al. (2004) The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J Virol 78: 5205-5215.
20. Moore PL, Ranchobe N, Lambson BE, Gray ES, Cave E, et al. (2009) Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog 5: e1000598.
21. Kelly HR, Urbanski M, Burda S, Zhong P, Konings F, et al. (2005) Neutralizing antibody patterns and viral escape in HIV-1 non-B subtype chronically infected treatment-naive individuals. Hum Antibodies 14: 89-99.
22. Frost SD, Wrin T, Smith DM, Kosakovsky Pond SL, Liu Y, et al. (2005) Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A 102: 18514-18519.
23. Deeks SG, Schweighardt B, Wrin T, Galovich J, Hoh R, et al. (2006) Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J Virol 80: 6155-6164.
24. Mahalanabis M, Jayaraman P, Miura T, Pereyra F, Chester EM, et al. (2009) Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers. J Virol 83: 662-672.
25. Bosch KA, Rainwater S, Jaoko W, Overbaugh J, (2010) Temporal analysis of HIV envelope sequence evolution and antibody escape in a subtype A-infected individual with a broad neutralizing antibody response. Virology 398: 115-124.
26. McKeating JA, Gow J, Goudsmit J, Pearl LH, Mulder C, et al. (1989) Characterization of HIV-1 neutralization escape mutants. AIDS 3: 777-784.
27. Aasa-Chapman MM, Holuigue S, Aubin K, Wong M, Jones NA, et al. (2005) Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection. J Virol 79: 2823-2830.
28. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, et al. (2002) The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1->2 mannose residues on the outer face of gp120. J Virol 76: 7306-7321.
29. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, et al. (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105: 7552-7557.
30. Bunnik EM, Lobbrecht MS, van Nuenen AC, Schuitemaker H Escape from autologous humoral immunity of HIV-1 is not associated with a decrease in replicative capacity. Virology 397: 224-230.
31. Aasa-Chapman MM, Seymour CR, Williams I, McKnight A, (2006) Novel envelope determinants for CCR3 use by human immunodeficiency virus. J Virol 80: 10884-10889.
32. Aasa-Chapman MM, Aubin K, Williams I, McKnight A, (2006) Primary CCR5 only using HIV-1 isolates does not accurately represent the in vivo replicating quasi-species. Virology 351: 489-496.
33. Sullivan N, Sun Y, Li J, Hofmann W, Sodroski J, (1995) Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol 69: 4413-4422.
34. Willey S, Aasa-Chapman MM, (2008) Humoral immunity to HIV-1: neutralisation and antibody effector functions. Trends in microbiology 16: 596-604.
35. Ferguson TA, Griffith TS, (2006) A vision of cell death: Fas ligand and immune privilege 10 years later. Immunol Rev 213: 228-238.
36. Brew BJ, Evans L, Byrne C, Pemberton L, Hurren L, (1996) The relationship between AIDS dementia complex and the presence of macrophage tropic and non-syncytium inducing isolates of human immunodeficiency virus type 1 in the cerebrospinal fluid. J Neurovirol 2: 152-157.
37. Gorry PR, Churchill M, Crowe SM, Cunningham AL, Gabuzda D, (2005) Pathogenesis of macrophage tropic HIV-1. Curr HIV Res 3: 53-60.
38. Wang TH, Donaldson YK, Brettle RP, Bell JE, Simmonds P, (2001) Identification of shared populations of human immunodeficiency virus type 1 infecting microglia and tissue macrophages outside the central nervous system. J Virol 75: 11686-11699.
39. Duenas-Decamp MJ, Peters PJ, Burton D, Clapham PR, (2009) Determinants flanking the CD4 binding loop modulate macrophage tropism of human immunodeficiency virus type 1 R5 envelopes. J Virol 83: 2575-2583.
40. Bunnik EM, Quakkelaar ED, van Nuenen AC, Boeser-Nunnink B, Schuitemaker H, (2007) Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient. J Virol 81: 525-531.
41. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, et al. (2005) Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79: 10108-10125.
42. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46: 1896-1905.
43. McKeating JA, Zhang YJ, Arnold C, Frederiksson R, Fenyo EM, et al. (1996) Chimeric viruses expressing primary envelope glycoproteins of human immunodeficiency virus type I show increased sensitivity to neutralization by human sera. Virology 220: 450-460.
44. Rambaut A, Grassly NC, Nee S, Harvey PH, (1996) Bi-De: an application for simulating phylogenetic processes. Comput Appl Biosci 12: 469-471.
45. Swofford DL, Waddell PJ, Huelsenbeck JP, Foster PG, Lewis PO, et al. (2001) Bias in phylogenetic estimation and its relevance to the choice between parsimony and likelihood methods. Syst Biol 50: 525-539.
46. Soda Y, Shimizu N, Jinno A, Liu HY, Kanbe K, et al. (1999) Establishment of a new system for determination of coreceptor usages of HIV based on the human glioma NP-2 cell line. Biochem Biophys Res Commun 258: 313-321.
47. Deng H, Unutmaz D, KewalRamani VN, Littman DR, (1997) Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature 388: 296-300.
48. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, et al. (2006) Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 80: 11776-11790.
49. Marchant D, Neil SJ, McKnight A, (2006) Human immunodeficiency virus types 1 and 2 have different replication kinetics in human primary macrophage culture. J Gen Virol 87: 411-418.
50. Richards KH, Aasa-Chapman MM, McKnight A, Clapham PR, Modulation of HIV-1 macrophage-tropism among R5 envelopes occurs before detection of neutralizing antibodies. Retrovirology 7: 48.